CLASS II Drug recall · Reported 14 Aug 2013 · FDA Enforcement Report

Excedrin Migraine (Acetaminophen 250 mg, Aspirin recalled

Novartis Consumer Health is recalling Excedrin Migraine (Acetaminophen 250 mg, Aspirin (Nsaid) 250 mg and Caffeine 65 mg), a), distributed nationwide in the US. The recall was initiated on 6 Jun 2013 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # a) 10116809, Exp 5/13 Foreign: Lot #s b) 10115644 Exp 5/13; 10118226 Exp 5/13; 10118227 Exp 6/13; 10118228 Exp 6/13; 10121956 Exp 8/13 and 10121957 Exp 8/13
Quantity recalled10,624,000 pouches

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-844-2013
FDA event ID
65422
Recalling firm
Novartis Consumer Health, Lincoln, NE
Classification
Class II
Status
Terminated
Recall initiated
6 Jun 2013
FDA classified
6 Aug 2013
Reported
14 Aug 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects
Drug class
Pain Medication

Timeline

6 Jun 2013Recall initiated by company
6 Aug 2013Classified by FDA+61 days
14 Aug 2013Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Defective container: products are packaged in pouches which may not have been fully sealed

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Excedrin Migraine (Acetaminophen 250 mg, Aspirin (NSAID) 250 mg and Caffeine 65 mg), a) 2-count tablets packaged in pouches, Distributed by Novartis Consumer Health, Inc., Parsippany, NJ, NDC 0067 203 702 Foreign packaging: b) Excedrin Migrana (Acetaminophen 250 mg, Aspirin 250 mg and 65 mg Caffeine) 2-ct pouches. The foreign packaging do not have NDC numbers

Where it was distributed

Nationwide, Puerto Rico, Brazil and Panama

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Defective container: products are packaged in pouches which may not have been fully sealed

Which lots are affected?

Lot # a) 10116809, Exp 5/13 Foreign: Lot #s b) 10115644 Exp 5/13; 10118226 Exp 5/13; 10118227 Exp 6/13; 10118228 Exp 6/13; 10121956 Exp 8/13 and 10121957 Exp 8/13

Where was it sold?

Nationwide, Puerto Rico, Brazil and Panama

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

3 other products · FDA event 65422

More recalls from Novartis Consumer Health

All 60